Cat. No. 4615
Chemical Name: 3,3,14,14-Tetramethylhexadecanedioi
Biological ActivityFree fatty acid 1 (FFA1/GPR40) receptor agonist; exhibits selectivity for FFA1 (GPR40) over GPR120. Also inhibits ATP citrate lyase; reduces intracellular triacylglycerol levels in muscle, inhibits lipogenesis and increases insulin sensitivity in rodents in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Hara et al (2009) Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch.Pharmacol. 380 247. PMID: 19471906.
Atkinson et al (2002) MEDICA 16 inhibits hepatic acetyl-CoA carboxylase and reduces plasma triacylglycerol levels in insulin-resistant JCR:LA-cp rats. Diabetes 51 1548. PMID: 11978655.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses MEDICA 16 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: MEDICA 16, supplier, MEDICA16, free, fatty, acid, receptors, 1, FFA1, FFAR1, GPR40, agonists, ATP, citrate, lyases, inhibitors, inhibits, lipogenesis, insulin, sensitivity, triacylglyerol, synthases, transferases, ACLY, Tocris Bioscience, Free Fatty Acid Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally availableA 971432
Potent and selective S1P5 agonistGLPG 0974
Potent FFA2 antagonistOgerin
Selective positive allosteric modulator at GPR68BGC 20-1531 hydrochloride
High affinity and selective EP4 antagonistMontelukast sodium
CysLT1 and GPR17 antagonist
December 3 - 7, 2016
San Francisco, CA,